UY35981A - Métodos para tratar el dolor asociado a la osteoartritis en una articulación con una formulación tópica de un compuesto de espirooxindol - Google Patents

Métodos para tratar el dolor asociado a la osteoartritis en una articulación con una formulación tópica de un compuesto de espirooxindol

Info

Publication number
UY35981A
UY35981A UY0001035981A UY35981A UY35981A UY 35981 A UY35981 A UY 35981A UY 0001035981 A UY0001035981 A UY 0001035981A UY 35981 A UY35981 A UY 35981A UY 35981 A UY35981 A UY 35981A
Authority
UY
Uruguay
Prior art keywords
methods
compound
osteoarthritis
spyrooxindol
articulation
Prior art date
Application number
UY0001035981A
Other languages
English (en)
Inventor
Fetell Michael
Malamut Richard
Michael J Lamson
Spiegelstein Ofer
Cohen Charles Jay
Goldberg Yigal Paul
Namdari Rostam
Price Nicola Anne
Proctor Katie Jane Webster
Original Assignee
Ivax Int Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ivax Int Gmbh filed Critical Ivax Int Gmbh
Publication of UY35981A publication Critical patent/UY35981A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

Métodos para tratar el dolor asociado a la osteoartritis en una articulación de un mamífero con una composición farmacéutica que comprende un compuesto de espiro-oxindol que tiene la siguiente fórmula: Los métodos proveen una penetración excelente del compuesto de espiro-oxindol en la membrana sinovial de la articulación afectada, que es útil para reducir de manera eficaz la intensidad del dolor y/o para aliviar el dolor, con una exposición sistémica mínima o insignificante.
UY0001035981A 2014-02-05 2015-02-05 Métodos para tratar el dolor asociado a la osteoartritis en una articulación con una formulación tópica de un compuesto de espirooxindol UY35981A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461936221P 2014-02-05 2014-02-05
US201462026554P 2014-07-18 2014-07-18

Publications (1)

Publication Number Publication Date
UY35981A true UY35981A (es) 2015-08-31

Family

ID=52544587

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035981A UY35981A (es) 2014-02-05 2015-02-05 Métodos para tratar el dolor asociado a la osteoartritis en una articulación con una formulación tópica de un compuesto de espirooxindol

Country Status (4)

Country Link
US (1) US20150216794A1 (es)
TW (1) TW201540299A (es)
UY (1) UY35981A (es)
WO (1) WO2015120151A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201636017A (zh) 2015-02-05 2016-10-16 梯瓦製藥國際有限責任公司 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法
WO2017218957A1 (en) * 2016-06-16 2017-12-21 Teva Pharmaceuticals International Gmbh Solid state forms of spiro-oxindole compounds
GB201706969D0 (en) * 2017-05-02 2017-06-14 Medherant Ltd Formulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
MX343215B (es) * 2010-02-26 2016-10-27 Xenon Pharmaceuticals Inc Composiciones farmacéuticas del compuesto espiro-oxindol para administración tópica y sus usos como agentes terapéuticos.

Also Published As

Publication number Publication date
US20150216794A1 (en) 2015-08-06
WO2015120151A1 (en) 2015-08-13
TW201540299A (zh) 2015-11-01

Similar Documents

Publication Publication Date Title
ECSP20005581A (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad nlrp
CL2018003588A1 (es) Uso de inhibidores de miostatina y terapias de combinación.
CO2018006714A2 (es) 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa
AR102553A1 (es) Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit
CL2016002516A1 (es) “compuestos derivados de espirociclo sustituidos, inhibidores atx; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, inflamaciones, dolor neuropático, enfermedades fibróticas, trombosis, entre otros”. pct
CL2016002812A1 (es) Uso de ácido 3-2,3,5,6-tetrafluoro-3-trifluorometoxi-bifenil-4-ilcarbamoil-tiofeno-2-carboxílico para preparar un medicamento útil para tratar una enfermedad ocular que es uveítis, ojo seco o causada por un adenovirus composición formulación.
CL2015002710A1 (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso.
CO2019005059A2 (es) Inhibidores de magl
CO2019005038A2 (es) Inhibidores de magl
BR112015023760A2 (pt) compostos e composições terapêuticas
CL2019003398A1 (es) Inhibidores pirazólicos de magl.
CL2016000009A1 (es) Tratamiento de rosacea papulopustular con ivermectina.
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
CL2017002170A1 (es) Desacetoxitubulisina h y análogos de esta.
DOP2016000336A (es) Derivados de isoindolina para uso en el tratamiento de una infeccion viral
CL2019001996A1 (es) Usos terapéuticos de un polvo de insectos.
CO7141430A2 (es) Formulaciones vesiculares para uso en el tratamiento del dolor o movilidad reducida de una articulación
CL2019002574A1 (es) Moduladores de la expresión de pcsk9.
DOP2016000007A (es) Pirazolpiridinas sustituidas
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
UY36373A (es) Compuestos para usarse en el tratamiento antihelmíntico
SV2016005293A (es) Compuestos de azol amido-sustituidos como inhibidores de tnks1 y/o tnks2
EA201791814A1 (ru) Имидазолильные трициклические еноны как антиоксидантные модуляторы воспаления
CL2015001446A1 (es) Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido.
UY35981A (es) Métodos para tratar el dolor asociado a la osteoartritis en una articulación con una formulación tópica de un compuesto de espirooxindol

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20220610